The Latest Breaking News from BMY

The stock market is expected to remain volatile in the near term as investors remain anxious about the Fed’s actions. Amid high recession worries, fundamentally strong healthcare stocks, Pfizer (PFE), Bristol-Myers Squibb (BMY), Amgen (AMGN), and Elevance Health (ELV), which have the potential to withstand any market downturns, could be…

The Fed is expected to keep hiking rates to achieve its target inflation rate. Amid rising volatility, investor sentiment toward dividend investing has been improving. Here are three quality dividend-paying stocks, Novartis (NVS), Bristol-Myers Squibb (BMY), and Canon (CAJ), which will ensure a steady passive income stream in 2023. Keep…

The pharmaceutical industry is evolving with personalized medicines and the rapid adoption of RPM technology, which should boost growth. Moreover, with a recession lurking, fundamentally strong pharma stocks AstraZeneca (AZN) and Bristol-Myers Squibb (BMY) might be ideal buys. However, SNDL (SNDL) might be best avoided. Keep reading to know why.

The stock market’s outlook seems choppy as investors weigh data on the state of the economy, labor market, and future rate increases by the Federal Reserve. With more volatility expected for the near term, one should consider safeguarding their portfolios with fundamentally sound stocks Coca-Cola (KO), Bristol-Myers Squibb (BMY), and…

Leading pharma company Bristol-Myers Squibb’s (BMY) fiscal year 2022 revenue and EPS were in line with analysts’ estimates. While BMY continues to advance its innovative portfolio and pipeline, is it a good dividend stock to pick up right now? Read more to find out.

The pharma industry has experienced tremendous growth in recent years. The industry should continue to grow, driven by the growing market for personalized medicine and e-pharmacies. Hence, pharma stocks Pfizer (PFE), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), and Zoetis (ZTS) might be worth buying for the long term. Also, these companies…

It's a new day at Bristol Myers, according to a company exec. But the drug giant's stock remains under pressure ahead of a patent cliff.

Monthly inflation inched up in January. Moreover, the Fed could be forced to raise the benchmark rate higher than forecasted. Amid this backdrop, it could be wise for investors to buy fundamentally strong stocks Coca-Cola (KO), Bristol-Myers Squibb (BMY), Cardinal Health (CAH), and Bluegreen Vacations Holding (BVH), currently trading under…

Although favorable macro data rekindled investor optimism, the Fed’s intention of raising rates to tame stubbornly high inflation could possibly tip the economy into recession. With anxiety escalating, it would be wise to add quality stocks Johnson & Johnson (JNJ) and Bristol-Myers Squibb (BMY) to your portfolio to sail through…

Cooling inflationary pressures, a slowdown in the Fed’s interest rate hikes, and easing recession fears are contributing to improved investor sentiment lately. Amid growing investor optimism, fundamentally sound stocks Bristol-Myers Squibb (BMY) and General Motors (GM) could be wise additions to your portfolio to start 2023 right. Continue reading….

The pharmaceutical industry is well-positioned for significant growth in the near future, given the growing demand for medicines and increasing R&D activities. Given the industry's inelastic demand, fundamentally strong pharma stocks AstraZeneca (AZN), Bristol-Myers Squibb (BMY), and GSK plc (GSK) might be solid long-term investments. Continue reading….